Seminars in Oncology
Volume 36, Issue 4 , Pages 338-346 , August 2009

Small Round Cell Sarcomas

  • Stephen L. Lessnick

      Affiliations

    • Huntsman Cancer Institute, Salt Lake City, UT
    • These authors contributed equally to this work.
    • ,
  • A. Paolo Dei Tos

      Affiliations

    • General Hospital of Treviso, Treviso, Italy
    • These authors contributed equally to this work.
    • ,
  • Poul H.B. Sorensen

      Affiliations

    • Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC, Canada
    • These authors contributed equally to this work.
    • ,
  • Palma Dileo

      Affiliations

    • Sarcoma Unit, Department of Medical Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
    • These authors contributed equally to this work.
    • ,
  • Laurence H. Baker

      Affiliations

    • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
    • These authors contributed equally to this work.
    • ,
  • Stefano Ferrari

      Affiliations

    • Istituto Ortopedico Rizzoli, Bologna, Italy
    • These authors contributed equally to this work.
    • ,
  • Kirsten Sundby Hall

      Affiliations

    • Division of Cancer Medicine and Radiotherapy, The Norwegian Radium Hospital, Rikshospitalet University Hospital, Oslo, Norway
    • These authors contributed equally to this work.
    • Corresponding Author InformationAddress correspondence to Kirsten Sundby Hall, MD, Division of Cancer Medicine and Radiotherapy. The Norwegian Radium Hospital, Rikshospitalet University Hospital, NO-0310 Oslo, Norway

References 

  1. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med. 1999;341:342–352
  2. Delattre O, Zucman J, Plougastel B, Desmaze C, Melot T, Peter M, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature. 1992;359:162–165
  3. Turc-Carel C, Aurias A, Mugneret F, Lizard S, Sidaner I, Volk C, et al. Chromosomes in Ewing's sarcoma (I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12)). Cancer Genet Cytogenet. 1988;32:229–238
  4. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: current status and outlook for the future. Med Pediatr Oncol. 2003;40:276–287
  5. McAllister NR, Lessnick SL. The potential for molecular therapeutic targets in Ewing's sarcoma. Curr Treat Options Oncol. 2005;6:461–471
  6. Delattre O, Zucman J, Melot T, Garau XS, Zucker JM, Lenoir GM, et al. The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med. 1994;331:294–299
  7. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701
  8. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol. 1998;16:1248–1255
  9. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol. 2005;23:548–558
  10. Turc-Carel C, Dal Cin P, Limon J, Li F, Sandberg AA. Translocation X;18 in synovial sarcoma. Cancer Genet Cytogenet. 1986;23:93
  11. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor. Cancer Res. 1994;54:2837–2840
  12. Sawyer JR, Tryka AF, Lewis JM. A novel reciprocal chromosome translocation t(11;22)(p13;q12) in an intraabdominal desmoplastic small round-cell tumor. Am J Surg Pathol. 1992;16:411–416
  13. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6:146–151
  14. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, Denny CT, et al. A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. Oncogene. 1995;10:1229–1234
  15. Peter M, Couturier J, Pacquement H, Michon J, Thomas G, Magdelenat H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene. 1997;14:1159–1164
  16. Urano F, Umezawa A, Hong W, Kikuchi H, Hata J. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun. 1996;219:608–612
  17. May WA, Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A. 1993;90:5752–5756
  18. May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 1993;13:7393–7398
  19. Ewing J. Diffuse Endothelioma of bone. Proc NY Pathol Soc. 1921;21:17–24
  20. Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res. 2004;64:8213–8221
  21. Kadin ME, Bensch KG. On the origin of Ewing's tumor. Cancer. 1971;27:257–273
  22. Dickman PS, Liotta LA, Triche TJ, Ewing's sarcoma. Ewing's sarcoma: characterization in established cultures and evidence of its histogenesis. Lab Invest. 1982;47:375–382
  23. Cavazzana AO, Miser JS, Jefferson J, Triche TJ. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol. 1987;127:507–518
  24. Torchia EC, Jaishankar S, Baker SJ. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res. 2003;63:3464–3468
  25. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C, et al. Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005;65:11459–11468
  26. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell. 2007;11:421–429
  27. Kovar H. Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol. 2005;15:189–196
  28. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24:7275–7283
  29. Smith R, Owen LA, Trem DJ, Wong JS, Whangbo JS, Golub TR, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 2006;9:405–416
  30. Kinsey M, Smith R, Lessnick SL. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma. Mol Cancer Res. 2006;4:851–859
  31. Owen LA, Lessnick SL. Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma. Cell Cycle. 2006;5:2049–2053
  32. Hancock JD, Lessnick SL. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature. Cell Cycle. 2008;7:250–256
  33. Baird K, Davis S, Antonescu CR, Harper UL, Walker RL, Chen Y, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005;65:9226–9235
  34. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE. 2008;3:e1965
  35. Fox CJ, Hammerman PS, Thompson CB. Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol. 2005;5:844–852
  36. Botti J, Djavaheri-Mergny M, Pilatte Y, Codogno P. Autophagy signaling and the cogwheels of cancer. Autophagy. 2006;2:67–73
  37. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672–676
  38. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122:927–939
  39. Yu L, Alva A, Su H, Dutt P, Freundt E, Welsh S, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science. 2004;304:1500–1502
  40. Ewing J. Diffuse endothelioma of bone. Proc NY Pathol Soc. 1921;21:17–24
  41. Stuart-Harris R, Wills EJ, Philips J, Langlands AO, Fox RM, Tattersall MH. Extraskeletal Ewing's sarcoma: a clinical, morphological and ultrastructural analysis of five cases with a review of the literature. Eur J Cancer Clin Oncol. 1986;22:393–400
  42. McTiernan AM, Cassoni AM, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. Improving outcomes after relapse in Ewing's sarcoma: analysis of 114 patients from a single institution. Sarcoma. 2006;83548
  43. Oberlin O, Rey A, Desfachelles AS, Philip T, Plantaz D, Schmitt C, et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l'Enfant. J Clin Oncol. 2006;24:3997–4002
  44. Ferrari S, Alvegard T, Luksch R, Tienghi A, Hall KS, Bernini G, et al. Non-metastatic Ewing's family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients (Preliminary results of the Italian/Scandinavian ISG/SSG III protocol). [abstract] J Clin Oncol. 2007;25:10014
  45. Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007;48:132–139
  46. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, et al. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group study. J Clin Oncol. 2007;25:4622–4627
  47. Vassal G, Couanet D, Stockdale E, Geoffray A, Geoerger B, Orbach D, et al. Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: a joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol. 2007;25:356–361
  48. Bisogno G, Riccardi R, Ruggiero A, Arcamone G, Prete A, Surico G, et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer. 2006;106:703–707
  49. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing's sarcoma family of tumors: current management. Oncologist. 2006;11:503–519
  50. Walterhouse DO, Lyden ER, Breitfeld PP, Qualman SJ, Wharam MD, Meyer WH. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol. 2004;22:1398–1403
  51. Saylors RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463–3469
  52. Saylors RL, Stewart CF, Zamboni WC, Wall DA, Bell B, Stine KC, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998;16:945–952
  53. Toretsky JA, Kalebic T, Blakesley V, LeRoith D, Helman LJ. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem. 1997;272:30822–30827
  54. LeRoith D, Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell. 2004;5:201–202
  55. Kalebic T, Tsokos M, Helman LJ. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. 1994;54:5531–5534
  56. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007;26:1932–1940
  57. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1190–1197
  58. A study of R1507 in patients with recurrent or refractory sarcoma. http:www.Clinicaltrials.gov, clinical trial NCT00642941. Accessed June 20, 2009.
  59. Angervall L, Enzinger FM. Extraskeletal neoplasm resembling Ewing's sarcoma. Cancer. 1975;36:240–251
  60. Soule EH, Newton W, Moon TE, Tefft M. Extraskeletal Ewing's sarcoma: a preliminary review of 26 cases encountered in the Intergroup Rhabdomyosarcoma Study. Cancer. 1978;42:259–264
  61. Kinsella TJ, Triche TJ, Dickman PS, Costa J, Tepper JE, Glaubiger D. Extraskeletal Ewing's sarcoma: results of combined modality treatment. J Clin Oncol. 1983;1:489–495
  62. Rud NP, Reiman HM, Pritchard DJ, Frassica FJ, Smithson WA. Extraosseous Ewing's sarcoma (A study of 42 cases). Cancer. 1989;64:1548–1553
  63. Raney RB, Asmar L, Newton WA, Bagwell C, Breneman JC, Crist W, et al. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol. 1997;15:574–582
  64. Gururangan S, Marina NM, Luo X, Parham DM, Tzen CY, Greenwald CA, et al. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing's tumor with Ewing's-directed therapy. J Pediatr Hematol Oncol. 1998;20:55–61
  65. Ahmad R, Mayol BR, Davis M, Rougraff BT. Extraskeletal Ewing's sarcoma. Cancer. 1999;85:725–731

 Stephen L. Lessnick is supported by the Terri Anna Perine Sarcoma Fund, the Liddy Shriver Sarcoma Initiative, American Cancer Society Research Scholar Grant No. MGO-111812, and a Huntsman Cancer Institute Director's Translational Research Initiative Grant. S.L.L. also acknowledges NIH support to Huntsman Cancer Institute via P30 CA042014. Poul H.B. Sorensen is supported by grants from the Canadian Institutes of Health Research (CIHR).

Disclosures Stephen L. Lessnick: Owns stock in Merck, Inc, the makers of vorinostat. Merck provided the vorinostat used in Dr Lessnick's studies.Laurence H. Baker: Hoffman-La Roche supports clinical trials and research by the Sarcoma Alliance for Research through Collaboration, on whose executive board Dr Baker is a member.

PII: S0093-7754(09)00106-7

doi: 10.1053/j.seminoncol.2009.06.006

Seminars in Oncology
Volume 36, Issue 4 , Pages 338-346 , August 2009

Article Tools

* Image Usage & Resolution